SavWatt USA, Inc. (PINK:SAVW), pioneers in LED lighting and the Green revolution, released recently that their first product has been approved and received Lighting Facts® Certification by the U.S. Department of Energy. As innovative LED lighting products emerge, the facts about LED lighting performance must hit the market with equal speed. Clear labeling on lighting performance is the critical link between innovation and successful market introduction. Lighting Facts® showcases LED luminaire manufacturers who commit to testing products and reporting performance results according to industry standards. For lighting buyers, designers, and energy efficiency programs, the Lighting Facts label provides information essential to evaluating products and identifying the best options.
SavWatt is leading the LED lighting revolution and setting the stage to obsolete the incandescent light bulb through the use of energy-efficient, environmentally friendly LED lighting. SavWatt is a market-leading innovator of LED lighting. SavWatt’s product families include LED fixtures, bulbs, Street Lights and Parking Lights.
Power3 Medical Products, Inc. (OTCBB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, recently disclosed that Power3 delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (NASDAQ:ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro®, Power3’s diagnostic test, and focused on Power3’s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3’s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3’s President and Chief Scientific Officer.
Power3 has filed several patent applications for its NuroPro® technology that are currently pending. Power3 also has a world-wide exclusive license from the Baylor College of Medicine in Houston, Texas. To date, Power3 has given 9 presentations on NuroPro at international scientific meetings in the United States, Europe and China, and has published 6 articles in peer-reviewed scientific journals on the subject. Power3 intends to publish these latest findings as well.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases.
Exide Technologies (Nasdaq:XIDE) (exide.com), reported its fiscal 2011 second quarter financial results for the period ended September 30, 2010.
Highlights of Fiscal 2011 Second Quarter and Year-to-Date Results:
* Net sales for the fiscal 2011 second quarter of $668.0 million compared to $631.8 million in the prior year quarter on estimated 2.3% higher unit volumes;
* Fiscal 2011 second quarter earnings before interest and taxes (EBIT) were $35.0 million compared to EBIT of $15.9 million in the fiscal 2010 second quarter;
* Net income in the current year period was $18.0 million or $0.22 per diluted share as compared to the prior year period net loss of $8.0 million or ($0.11) per share; and
* Adjusted net income for the fiscal 2011 second quarter was $13.9 million or $0.17 per share as compared to adjusted net income of $3.8 million or $0.05 per share in the fiscal 2010 comparative period.
Exide Technologies, together with its subsidiaries, engages in the manufacture and supply of lead-acid batteries for the transportation and industrial energy applications.
Pernix Therapeutics Holdings, Inc. (NYSE Amex:PTX), an integrated specialty pharmaceutical company primarily focused on the pediatric market, today announced results for the three and nine months ended September 30, 2010.
Third Quarter 2010 Highlights
* Acquired Macoven Pharmaceuticals – pharmaceutical company focused on the development of generic products and the sale of authorized generic products; recorded a pre-tax gain of $882,000 in connection with the acquisition;
* Continued IP Investment - acquired TCT control delivery technology;
* Increased Profitability – income before taxes and non-controlling interest increased to $3,248,000;
* Strengthened Financial Position – secured $10,000,000 revolving line of credit with Regions Bank that matures in September 2012;
* Authorized Share Repurchase – repurchased 2,052,000 shares of common stock through open market purchases and a privately negotiated transaction with an employee;
* Maintained Strong Cash Position – approximately $8,665,000 of cash, cash equivalents and restricted cash as of September 30, 2010.
Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, engages in the acquisition, development, marketing, and distribution of branded pharmaceutical products to meet unmet medical needs, primarily in pediatrics.
America’s largest golf retailer is giving more than 5,000 junior golfers a way to improve their games and save money at the same time. Golfsmith International, Inc., (NASDAQ:GOLF) has struck a four-year agreement with the American Junior Golf Association, Inc. (AJGA). As the Preferred Golf Retailer of the AJGA, Golfsmith will provide AJGA Member Days, discounts to the AJGA’s 5,300 members and 50% off on swing evaluations from GolfTEC, America’s #1 lesson provider.
Golfsmith International Holdings, Inc. is a specialty retailer of golf and tennis equipment, apparel and accessories.
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for SavWatt USA, Inc. (OTC:SAVW). Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).